Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes

Clare B. Kelly; Carol L. Wagner; Judith R. Shary; Misti J. Leyva; Jeremy Y. Yu; Alicia J. Jenkins; Alison J. Nankervis; Kristian F. Hanssen; Satish K. Garg; James A. Scardo; Samar M. Hammad; Christopher E. Aston; Timothy J. Lyons

doi:10.3390/nu12072048

Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes

Clare B. Kelly, Carol L. Wagner, Judith R. Shary, Misti J. Leyva, Jeremy Y. Yu, Alicia J. Jenkins, Alison J. Nankervis, Kristian F. Hanssen, Satish K. Garg, James A. Scardo, Samar M. Hammad, Christopher E. Aston, Timothy J. Lyons^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

88 Downloads (Pure)

Abstract

The risk for preeclampsia (PE) is enhanced ~4-fold by the presence of maternal type 1 diabetes (T1DM). Vitamin D is essential for healthy pregnancy. We assessed the total, bioavailable, and free concentrations of plasma 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)₂D), and vitamin D binding protein (VDBP) at ~12, ~22, and ~32 weeks’ gestation (“Visits” (V) 1, 2, and 3, respectively) in 23 T1DM women who developed PE, 24 who remained normotensive, and 19 non-diabetic, normotensive women (reference controls). 25(OH)D deficiency was more frequent in diabetic than non-diabetic women (69% vs. 22%, p < 0.05), but no measure of 25(OH)D predicted PE. By contrast, higher 1,25(OH)₂D concentrations at V2 (total, bioavailable, and free: p < 0.01) and V3 (bioavailable: p < 0.05; free: p < 0.01), lower concentrations of VDBP at V3 (p < 0.05), and elevated ratios of 1,25(OH)₂D/VDBP (V2, V3: p < 0.01) and 1,25(OH)₂D/25(OH)D (V3, p < 0.05) were all associated with PE, and significance persisted in multivariate analyses. In summary, in women with T1DM, concentrations of 1,25(OH)₂D were higher, and VDBP lower, in the second and third trimesters in women who later developed PE than in those who did not. 1,25(OH)₂D may serve as a new marker for PE risk and could be implicated in pathogenesis.

Original language	English
Article number	2048
Number of pages	12
Journal	Nutrients
Volume	12
Issue number	7
DOIs	https://doi.org/10.3390/nu12072048
Publication status	Published - 10 Jul 2020

Bibliographical note

Funding Information:
Funding: This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado.

Funding Information:
This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. Acknowledgments: The skilled and dedicated assistance of the following individuals for the clinical components of the study is acknowledged, none of whom were compensated for their contributions. Spartanburg Regional Hospital, Spartanburg, SC: Jill Cole. University of Melbourne, Australia: Christine Knight, Jennifer Conn, Susan Hiscock, Jeremy Oats, and Peter Wein. University of Oklahoma, Oklahoma City, OK: Azar Dashti.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

1,25-dihydroxyvitamin D
25-hydroxyvitamin D
Preeclampsia
Pregnancy
Type 1 diabetes
Vitamin D
Vitamin D binding protein

ASJC Scopus subject areas

Food Science
Nutrition and Dietetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/nu12072048Licence: CC BY

Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes
Copyright 2020 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited
Final published version, 1.06 MBLicence: CC BY

Cite this

@article{62424264c26a4bebb430d65a6b4e6e36,

title = "Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes",

abstract = "The risk for preeclampsia (PE) is enhanced ~4-fold by the presence of maternal type 1 diabetes (T1DM). Vitamin D is essential for healthy pregnancy. We assessed the total, bioavailable, and free concentrations of plasma 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and vitamin D binding protein (VDBP) at ~12, ~22, and ~32 weeks{\textquoteright} gestation (“Visits” (V) 1, 2, and 3, respectively) in 23 T1DM women who developed PE, 24 who remained normotensive, and 19 non-diabetic, normotensive women (reference controls). 25(OH)D deficiency was more frequent in diabetic than non-diabetic women (69% vs. 22%, p < 0.05), but no measure of 25(OH)D predicted PE. By contrast, higher 1,25(OH)2D concentrations at V2 (total, bioavailable, and free: p < 0.01) and V3 (bioavailable: p < 0.05; free: p < 0.01), lower concentrations of VDBP at V3 (p < 0.05), and elevated ratios of 1,25(OH)2D/VDBP (V2, V3: p < 0.01) and 1,25(OH)2D/25(OH)D (V3, p < 0.05) were all associated with PE, and significance persisted in multivariate analyses. In summary, in women with T1DM, concentrations of 1,25(OH)2D were higher, and VDBP lower, in the second and third trimesters in women who later developed PE than in those who did not. 1,25(OH)2D may serve as a new marker for PE risk and could be implicated in pathogenesis.",

keywords = "1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, Preeclampsia, Pregnancy, Type 1 diabetes, Vitamin D, Vitamin D binding protein",

author = "Kelly, {Clare B.} and Wagner, {Carol L.} and Shary, {Judith R.} and Leyva, {Misti J.} and Yu, {Jeremy Y.} and Jenkins, {Alicia J.} and Nankervis, {Alison J.} and Hanssen, {Kristian F.} and Garg, {Satish K.} and Scardo, {James A.} and Hammad, {Samar M.} and Aston, {Christopher E.} and Lyons, {Timothy J.}",

note = "Funding Information: Funding: This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. Funding Information: This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. Acknowledgments: The skilled and dedicated assistance of the following individuals for the clinical components of the study is acknowledged, none of whom were compensated for their contributions. Spartanburg Regional Hospital, Spartanburg, SC: Jill Cole. University of Melbourne, Australia: Christine Knight, Jennifer Conn, Susan Hiscock, Jeremy Oats, and Peter Wein. University of Oklahoma, Oklahoma City, OK: Azar Dashti. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = jul,

day = "10",

doi = "10.3390/nu12072048",

language = "English",

volume = "12",

journal = "Nutrients",

issn = "2072-6643",

publisher = "MDPI",

number = "7",

}

TY - JOUR

T1 - Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes

AU - Kelly, Clare B.

AU - Wagner, Carol L.

AU - Shary, Judith R.

AU - Leyva, Misti J.

AU - Yu, Jeremy Y.

AU - Jenkins, Alicia J.

AU - Nankervis, Alison J.

AU - Hanssen, Kristian F.

AU - Garg, Satish K.

AU - Scardo, James A.

AU - Hammad, Samar M.

AU - Aston, Christopher E.

AU - Lyons, Timothy J.

N1 - Funding Information: Funding: This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. Funding Information: This work was supported by Research Grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-844) and Novo Nordisk to TJL, and by NIH (NCRR) Grants M01-RR-1070 and M01 RR-14467 to the General Clinical Research Centers at MUSC and OUHSC, respectively. Support from Novo Nordisk enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. Acknowledgments: The skilled and dedicated assistance of the following individuals for the clinical components of the study is acknowledged, none of whom were compensated for their contributions. Spartanburg Regional Hospital, Spartanburg, SC: Jill Cole. University of Melbourne, Australia: Christine Knight, Jennifer Conn, Susan Hiscock, Jeremy Oats, and Peter Wein. University of Oklahoma, Oklahoma City, OK: Azar Dashti. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/7/10

Y1 - 2020/7/10

N2 - The risk for preeclampsia (PE) is enhanced ~4-fold by the presence of maternal type 1 diabetes (T1DM). Vitamin D is essential for healthy pregnancy. We assessed the total, bioavailable, and free concentrations of plasma 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and vitamin D binding protein (VDBP) at ~12, ~22, and ~32 weeks’ gestation (“Visits” (V) 1, 2, and 3, respectively) in 23 T1DM women who developed PE, 24 who remained normotensive, and 19 non-diabetic, normotensive women (reference controls). 25(OH)D deficiency was more frequent in diabetic than non-diabetic women (69% vs. 22%, p < 0.05), but no measure of 25(OH)D predicted PE. By contrast, higher 1,25(OH)2D concentrations at V2 (total, bioavailable, and free: p < 0.01) and V3 (bioavailable: p < 0.05; free: p < 0.01), lower concentrations of VDBP at V3 (p < 0.05), and elevated ratios of 1,25(OH)2D/VDBP (V2, V3: p < 0.01) and 1,25(OH)2D/25(OH)D (V3, p < 0.05) were all associated with PE, and significance persisted in multivariate analyses. In summary, in women with T1DM, concentrations of 1,25(OH)2D were higher, and VDBP lower, in the second and third trimesters in women who later developed PE than in those who did not. 1,25(OH)2D may serve as a new marker for PE risk and could be implicated in pathogenesis.

AB - The risk for preeclampsia (PE) is enhanced ~4-fold by the presence of maternal type 1 diabetes (T1DM). Vitamin D is essential for healthy pregnancy. We assessed the total, bioavailable, and free concentrations of plasma 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and vitamin D binding protein (VDBP) at ~12, ~22, and ~32 weeks’ gestation (“Visits” (V) 1, 2, and 3, respectively) in 23 T1DM women who developed PE, 24 who remained normotensive, and 19 non-diabetic, normotensive women (reference controls). 25(OH)D deficiency was more frequent in diabetic than non-diabetic women (69% vs. 22%, p < 0.05), but no measure of 25(OH)D predicted PE. By contrast, higher 1,25(OH)2D concentrations at V2 (total, bioavailable, and free: p < 0.01) and V3 (bioavailable: p < 0.05; free: p < 0.01), lower concentrations of VDBP at V3 (p < 0.05), and elevated ratios of 1,25(OH)2D/VDBP (V2, V3: p < 0.01) and 1,25(OH)2D/25(OH)D (V3, p < 0.05) were all associated with PE, and significance persisted in multivariate analyses. In summary, in women with T1DM, concentrations of 1,25(OH)2D were higher, and VDBP lower, in the second and third trimesters in women who later developed PE than in those who did not. 1,25(OH)2D may serve as a new marker for PE risk and could be implicated in pathogenesis.

KW - 1,25-dihydroxyvitamin D

KW - 25-hydroxyvitamin D

KW - Preeclampsia

KW - Pregnancy

KW - Type 1 diabetes

KW - Vitamin D

KW - Vitamin D binding protein

U2 - 10.3390/nu12072048

DO - 10.3390/nu12072048

M3 - Article

C2 - 32664257

AN - SCOPUS:85088035024

SN - 2072-6643

VL - 12

JO - Nutrients

JF - Nutrients

IS - 7

M1 - 2048

ER -

Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this